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The prognostic significance of blood pressure elevation
and its associated characteristics in patients recovered
from myocardial infarction was studied in the placebo
group (n = 2,789) of the Coronary Drug Project. Age,
relative body weight, heart rate and ST depression on
the electrocardiogram were important positive corre-
lates of hypertension measured at baseline. The relation
of uric acid and elevated plasma glucose levels to in-
creased blood pressure could be partially explained as
side effects of thiazide diuretic therapy. A "high nor-
mal" baseline blood pressure best predicted the devel-
opment of hypertension among survivors of myocardial
mfarction. Both combined systolic and diastolic hyper-
Hypertension is a major risk factor for initial coronary events,
that i' s , angina, myocardial infatction and sudden cardiac
death. This has been documented (1-9) extensively for el-
evation of both systolic and diastolic blood pressures. Al-
though this relation is wen established, little information is
available about the clinical significance of systolic and di-
astolic blood pressure levels in persons after recovery from
one or more episodes of myocardial infarction. The placebo
group in the Coronary Drug Project provided us with the
opportunity to study this issue.
This report addresses the following questions:
1) What are the demographic, clinical, electrocardio-
graphic, biochemical and hematologic correlates of systolic
and diastolic hypertension (as measured at baseline) in men
recovered from myocardial infarction?
2) What variables measured at baseline correlate with
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tension and isolated systolic hypertension were adverse
prognostic factors.
Changes in blood pressure, including the prognostic
implications of a decrease in pressure, were also ana-
Iyzedin the subset of patients who sustained a recurrent
nonfatalmyocardialinfarction. Decreasesin systolic (mean
7.9 mm Hg) and diastolic (mean 3.6 mm Hg) blood pres-
sure were sustained in this subset. Patients whose blood
pressure decreased after recurrent myocardial infarc-
tion tended to have higher mortality rates than those of
comparable patients whose blood pressure increased or
remained unchanged.
development over time of systolic and diastolic hypertension
among survivors of myocardial infarction?
3) What is the prognostic significance of baseline systolic
and diastolic blood pressure levels for subsequent coronary
and cerebrovascular events and survival in patients re-
covered from myocardial infarction?
4) What are the effects of recurrent myocardial infarction
on systolic and diastolic blood pressures?
5) What is the effect on prognosis of a decrease in blood
pressure after a recurrent myocardial infarction?
Methods
Study design. The background, design and organization
of the Coronary Drug Project have been described (10-14).
Its primary objective was to evaluate the efficacy and safety
of several lipid-influencing drugs in the long-term manage-
ment of men after recovery from myocardial infarction. For
this purpose 8,341 men were recruited by the 53 Coronary
Drug Project clinical centers and randomly assigned to six
treatment groups. Approximately one-third of the patients
(2,789 men) were allocated to a placebo group; data from
this group of patients form the basis for this report.
Study patients. Patients enrolled in the Coronary Drug
Project were 30 to 64 year old men (mean age 52.4; 93%
white) with a history of one or more electrocardiographically
documented episodes of myocardial infarction. Entry into
the Coronary Drug Project was limited to patients in New
York Heart Association functional class I or II (15) who
were free of a specified list of diseases. All patients had
had their last myocardial infarction at least 3 months (mean
0735-1097/84/$3.00
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= 36) before enrollment and had had no recent worsening
of their coronary heart disease or any other major illness.
Extensive standardized baseline data (demographic, clini-
cal; electrocardiographic, biochemical and hematologic) were
collected for each patient. Baseline measurements were taken
before entry into the study, 3 or more months after the
qualifying myocardial infarction.
Appendix A lists the 40 baseline variables from which
adjusting variables were chosen. These included three casual
blood pressure determinations at 1 month intervals. The
three systolic blood pressure and three diastolic blood pres-
sure measurements were averaged and the mean of each
was used as a single baseline variable for each of the 2,789
men randomized to the placebo group. Blood pressure levels
were not a basis for exclusion from the study.
Follow-up. All men in the Coronary Drug Project were
followed up for a minimum of 5 years with clinic visits at
4 month intervals. At the baseline visit and at each annual
clinic visit, the patient was instructed to come to the clinic
in a fasting state; for nonannual visits a "fat-free" state was
required. At each visit, blood pressure was measured with
the patient either supine or sitting with the forearm at the
level of the heart. Diastolic blood pressure determination
used the fifth phase (disappearance of sound) as the criterion
(16).
Data sent to the Coordinating Center included "events"
such as death, recurrent nonfatal myocardial infarction, in-
termediate coronary episodes, angina pectoris, stroke, in-
termittent cerebral ischemic attacks and venous thromboem-
bolism. The diagnoses of these events were established by
the study clinic physician; diagnostic criteria are given in
Appendix B.
Analyses. This report analyzes the 5 year follow-up data
from several cohorts.
1) Total cohort. All 2,789 men randomized to placebo
therapy constitute the total cohort. Analysis of the relation
of blood pressure to long-term prognosis focuses on three
end points: mortality from all causes; recurrent major coro-
nary events (defined as definite nonfatal myocardial infarc-
tion and fatal coronary events) and combined cerebrovas-
cular events (defined as the combination of fatal stroke,
nonfatal stroke [definite or suspected] and intermittent ce-
rebral ischemic attacks [definite or suspectedl).
2) Normotensive cohort. The 1,630 men with a baseline
systolic blood pressure of less than 140 mm Hg and a base-
line diastolic blood pressure of less than 90 mm Hg and
who used neither antihypertensive nor diuretic drugs at the
baseline visit constitute the normotensive cohort.
3) Recurrent myocardial infarction cohort. During the
5 year follow-up period, 347 men sustained definite recur-
rent nonfatal myocardial infarction and 69 men had sus-
pected recurrent myocardial infarction. These groups were
compared with men who did not have recurrent myocardial
infarction. A randomly determined follow-up visit was as-
signed for each patient in the comparison group to match
the distribution of follow-up visits in the group with definite
recurrent myocardial infarction. The criterion that patients
must have had a recent premyocardial infarction clinic visit*
for evaluation limited the analyses to 326 men in the myo-
cardial infarction cohort, 68 meri in the suspected myo-
cardial infarction cohort and 1,822 men in the nonmy-
ocardial infarction cohort. Additional analyses requiring
three visits before and three visits after myocardial infarction
further restricted analyses to 186 men in the myocardial
infarction cohort, 58 men in the suspected myocardial in-
farction cohort and 1,222 men in the nonmyocardial in-
farction cohort.
In all three cohorts, the men not receiving drugs influ-
encing blood pressure (that is, diuretic and nondiuretic an-
tihypertensive medication) at entry into the Coronary Drug
Project, called the no medication cohort, were subsequently
examined separately.
Bloodpressure definitions. The following criteria were
used for blood pressure definitions.
Baseline systolic hypertension. t
1. Average of three baseline systolic blood pressures of 140
mm Hg or greater and/or either of the following at two
of the three baseline visits:
2. Antihypertensive drug (nondiuretic) use
3. Diuretic drug use without digitalis use
Baseline diastolic hypertension. t
1. Average of three baseline diastolic blood pressures of
90 mm Hg or greater and/or either of the following at
two of the three baseline visits:
2. Antihypertensive drug (nondiuretic) use
3. Diuretic drug use without digitalis use
Development of systolic hypertension. t Any combina-
tion of two or all three of the following at two consecutive
follow-up visits within 5 years after entry into the study:
1. Systolic blood pressure of 140 mm Hg or greater
2. Antihypertensive drug (nondiuretic) use
3. Diuretic drug use without digitalis use
Development of diastolic hypertension. t Any combi-
nation of two or all three of the following at two consecutive
follow-up visits within 5 years after entry into the study:
1. Diastolic blood pressure of 90 mm Hg or greater
2. Antihypertensive drug (nondiuretic) use
3. Diuretic drug use without digitalis use (see later)
"Recent premyocardial infarction clinic visit is defined as that follow-
up visit immediately before the recurrent myocardial infarction or one visit
earlier if the immediately prior clinic appointment was not kept.
tDefined as 1 if conditions are met, 0 if otherwise.
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The inclusion of diuretic use as part of the definition of
hypertension makes an assumption that clearly is not valid
for every Coronary Drug Project patient taking diuretic drugs
without digitalis; on occasion such patients could have been
treated with diuretic drugs to decrease fluid retention
(congestive heart failure) without concomitant use of digi-
talis; hypertension need not have been present. A definition
of hypertension that does not include diuretic drug use does
not alter the findings presented in this report (except that
the use of diuretic drugs becomes a correlate of hypertension).
To assess further the relation of baseline hypertension
to 5 year prognosis, an average level of three baseline sys-
tolic blood pressures of 140 mm Hg or greater and an av-
erage level of three baseline diastolic blood pressures of 90
mm Hg or greater were used to divide the placebo group
of patients into four groups:
Normotension: systolic blood pressure less than 140 mm
Hg and diastolic blood pressure less than 90 mm Hg.
Isolated systolic hypertension: systolic blood pressure of
140 mm Hg or greater and diastolic blood pressure less than
90 mm Hg.
Isolated diastolic hypertension: diastolic blood pressure
of 90 mm Hg or greater and systolic blood pressure less
than 140 mm Hg.
Combined systolic and diastolic hypertension: systolic
blood pressure of 140 mm Hg or greater and diastolic blood
pressure of 90 mm Hg or greater.
Statistical methods. The principal statistical method used
was linear regression, both univariate and multivariate. Ap-
pendi x A lists 40 entry characteristics, 19 of which were
chosen as adjusting variables. Nineteen other variables
(electrocardiographic characteristics, use of medications and
history of clinical conditions) were excluded because they
were considered a consequence rather than a possible cause
of the two elevated blood pressure variables. A t value
(regression coefficient divided by its standard error) was
used to evaluate statistical significance of the regression
coefficient. The partial correlation (the correlation of each
independent variable with the dependent variable removing
the effect of variables already in the equation) and the mul-
tiple R (the correlation of the dependent variable with the
predicted value) are reported for regression analyses, Stu-
dent's t test for paired observations was used to compare
pre- and postmyocardial infarction blood pressure levels.
Multiple response variables and subgroups complicate
the interpretation of conventional tests of significance.
Multiple testing increases the probability that one or more
comparisons will appear significant by chance alone. For
this reason, a result is not considered as statistically sig-
nificant unless it achieves at least the nominal 1.0% (p ~
0.01) level of significance (t 2: 2.58).
Results
The distribution of baseline systolic and diastolic blood
pressure levels for the total cohort of 2,789 men is presented
in Figure 1. The distribution of systolic blood pressure was
moderately skewed to the right; its coefficient of variation
was consequently somewhat greater than that for diastolic
blood pressure (13.0 versus 11.5). The mean blood pressure
values were 130.6 and 81.7 mm Hg, respectivey.
Correlates of baseline blood pressure (Table 1). Eleven
of the 38 baseline variables (use of antihypertensive drugs,
age, 1 hour glucose level, relative body weight, ST depres-
sion, use of diuretic drugs, serum uric acid, time since last
myocardial infarction, fasting glucose, triglycerides, heart
rate on electrocardiogram) in the simple correlation matrix
generated for the total cohort had correlation coefficients (r)
with systolic blood pressure or diastolic blood pressure, or
both, of 0.10 or greater and none had r values less than
- 0.10. Most of these significantly positive r values also
applied to the no medication cohort.
Correlates of baseline systolic and diastolic hyperten-
sion (Table 2). The prevalence of systolic and diastolic
hypertension at baseline was 30.6 and 23.7%, respectively.
Eight of the baseline variables in the simple correlation
matrix generated for the total cohort had correlation coef-
ficients with baseline systolic or diastolic hypertension, or
both, of O.10 or greater and none had correlation coefficients
less than - 0.10. Because baseline hypertension (as defined)
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Table 1. Simple Correlation Coefficients Between Baseline Systolic and Diastolic Blood Pressure and Other
Baseline Characteristics*
Simple Correlation Coefficient
Total Cohort (n = 2,789) No Med Cohort (n=2,216)
SBP DBP SBP DBP
Use of antihypertensive drugs 0.322 0.282 N/A N/A
Age 0.195 -0.013 0.187 -0.016
I hour glucose 0.175 0.109 0.155 0.089
Relative body weight 0.174 0.236 0.180 0.236
ST depression 0.171 0.090 0.116 0.053
Use of diuretic drugs 0.170 0.163 N/A N/A
Uric acid 0.136 0.162 0.127 0.130
Time since last myocardial infarction 0.127 0.081 0.124 0.076
Fasting glucose 0.116 0.080 0.096 0.054
Triglycerides 0.092 0.104 0.088 0.107
Heart rate on electrocardiogram 0.091 0.140 0.133 0.177
*Only variables with coefficients e 0.10 with either systolic blood pressure (SBP) or diastolic blood pressure (DBP) in either cohort are included;
variables were selected from the other 38 (omitting systolic blood pressure and diastolic blood pressure) baseline characteristics listed in Appendix A.
N/A = not applicable.
is a function of baseline blood pressure level, most of these
variables correlated with baseline systolic or diastolic blood
pressure, or both. Although directly related to baseline sys-
tolic hypertension, age did not correlate with baseline di-
astolic hypertension. Relative body weight and 1 hour glu-
cose correlated with both baseline systolic and diastolic
hypertension. The level of serum uric acid showed a strong
correlation with both systolic and diastolic hypertension. A
correlation between heart rate and diastolic hypertension
was present in the no medication cohort.
Correlates of development of systolic and diastolic
hypertension (Table 3). Among the 1,547 men in the nor-
motensive cohort who were present for at least two con-
secutive follow-up visits, 636 (41.1 %) developed systolic
hypertension and 520 (33.6%) developed diastolic hyper-
tension during the 5 years of follow-up. The five baseline
variables most predictive for the development of systolic
and diastolic hypertension, respectively, are listed in Table
3. A "high normal" baseline blood pressure was by far the
best independent predictor of the development of future
hypertension. There is a strong direct correlation of age with
the development of systolic hypertension. Relative body
weight was directly correlated with the development of both
systolic and diastolic hypertension. Time from last myo-
cardial infarction to entry into the Coronary Drug Project
was inversely related to the development of systolic hyper-
tension. Fasting plasma glucose level was inversely asso-
ciated with the development of diastolic hypertension. There
was no correlation with 1 hour glucose level.
The regression coefficients from the five variable regres-
Table 2. Simple Correlation Coefficients Between Baseline Systolic and Diastolic Hypertension and Other Baseline Characteristics*
Simple Correlation Coefficient
Total Cohort (n = 2,789) No Med Cohort (n=2,216)
SBP: DBP: SBP: DBP:
HPT HPT HPT HPT
Age 0.183 0.025 0.182 -0.013
Uric acid 0,169 0.190 0.094 0.090
I hour glucose 0.161 0.098 0.127 0.060
Relative body weight 0.148 0.181 0.114 0.152
ST depression 0.131 0.080 0.088 0.024
Fasting glucose 0.114 0.069 0.084 0.026
Cardiomegaly 0.110 0.084 0.064 0.028
Time since last myocardial infarction 0.107 0.085 0.101 0.068
Heart rate on electrocardiogram 0.036 0.086 0.080 0.132
*Only variables with coefficients ;::, 0.10 with either systolic hypertension (SBP HPT) or diastolic hypertension (DBP HPT) in either cohort are
included; variables were selected from the other 35 (omitting systolic blood pressure, diastolic blood pressure, digitalis use, diuretic drug use, antihy-
pertensive agent use) baseline characteristics listed in Appendix A. Other abbreviations as in Table I.
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Table 3. Development of Systolic and Diastolic Hypertension During 5 Years and Relation to Other Baseline Variables: Baseline
Normotensive Cohort (n= 1,547)
-_._----------------------'------------------
Part I: Regression and Correlation Coefficients
Baseline Variable Simple Correlation Coefficient Partial Correlation Coefficient Regression Coefficient
-_._----------------------------------------
Development of Systolic Hypertension
--------------------------------------------
Systolic blood pressure
Age
Time sin, e last myocardial infarction
Relative hody weight
Total bilirubin
Intercept
Mult R 00 0.444
0.417
0.160
0,001
0.110
-0.066
0.398
0.144
-0.065
0.064
-0.057
0.02089
0.00915
-0.01008
0.21607
-0.11000
-2.75731
Development of Diastolic Hypertension
Diastolic blood pressure
Systolic hlood pressure
Relative body weight
Fasting glucose
White blood count
Intercept
Mult R = 0.381
0.345
0,304
0.156
-0.034
-0.041
0.198
0.120
0.101
-0,061
-0.047
0,01785
0.00718
0.33868
-0.00138
-0,00001
-2.09188
Part 2: Observed Event Rate by Quintile of Expected Risk for Development of Systolic and Diastolic Hypertension During 5 Years of Follow-up
Calculated From Five Variable Regression Model
Systolic Hypertension Diastolic Hypertension
Quintik Denominator Numerator Rate Numerator Rate
I 309 42 13.6 28 9.1
2 309 73 23.6 71 23.0
3 310 123 39,7 90 29.0
4 310 175 56.5 140 45.3
5 309 223 72.2 19\ 61.8
Total 1.547 636 41.1 520 33.6
sion analysis were used to compute a risk score for devel-
opment of systolic and diastolic hypertension for each man.
The 10 variable regression analysis for systolic hypertension
(adding functional class, use of digitalis, T wave findings,
urea nitrogen level and serum uric acid) and for diastolic
hypertension (adding time since last myocardial infarction,
use of oral hypoglycemic agents, number of previous myo-
cardial infarctions, history of angina pectoris and urea ni-
trogen level) did not significantly alter the outcome. The
men were then ordered by quintile from low to high risk
score. and the actual observed rate of development of hy-
pertension was determined for each quintile (Table 3). There
was a progressive increase in the development of both sys-
tolic and diastolic hypertension by quintile. These variables
may have clinical relevance with respect to identifying peo-
ple more likely to develop hypertension over time.
Prognostic significance of baseline systolic and dia-
stolic blood pressure elevation. In the total cohort, men
with elevated systolic blood pressure at entry into the Coro-
nary Drug Project (baseline) had a higher 5 year unadjusted
rate of occurrence of all three end points (mortality from
all causes, major coronary events and combined cerebro-
vascular events) than did men with a normal systolic blood
pressure (Fig. 2). The t values of 3.66 to 4.15 for the systolic
blood pressure coefficients for the univariate linear regres-
sion analysis indicate that systolic blood pressure in the total
cohort was related to prognosis with p values less than 0.0 I.
After control for 19 baseline variables (Appendix A), the
association between an elevated systolic blood pressure and
death from all causes at 5 years was reduced, but the as-
sociation remained statistically significant for major coro-
nary events and combined cerebrovascular events (Fig. 2).
Men with an elevated systolic blood pressure in the corre-
sponding no medication cohort had a higher mortality rate
with statistically significant (p < 0.01) elevated systolic
blood pressure coefficients for major coronary events and
combined cerebrovascular events.
Clear-cut associations were less evident for elevated di-
astolic blood pressure. Univariate analyses for the total
cohort showed statistically significant elevated diastolic blood
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pressure coefficients only for the incidence of major coro-
nary events (Fig. 3). After adjustment for 19 baseline vari-
ables, a significant association between increased diastolic
blood pressure and combined cerebrovascular events also
became evident. No statistically significant association be-
tween elevated diastolic blood pressure and prognosis was
evident for the no medication cohort.
To assess further the relation of baseline hypertension
to 5 year prognosis, levels of systolic blood pressures of
140 mm Hg or greater and diastolic blood pressure of 90
mm Hg or greater were used to classify the patients in the
placebo group into the four subsets defined previously. Men
with combined hypertension had higher unadjusted and ad-
justed event rates for all three end points than did normo-
tensive men (Fig. 4). However, the higher rates were sta-
tistically significant only for combined cerebrovascular events.
Men with isolated systolic hypertension had a statistically
significant higher unadjusted rate for mortality from all causes
than did normotensive men. The risk for men with isolated
diastolic hypertension did not differ significantly from that
for normotensive men for any end point. The same asso-
ciations existed for the no medication cohort, but were not
statistically significant.
Blood pressure decrease after recurrent myocardial
infarction. Statistically significant decreases in mean sys-
tolic blood pressure (7.9 mm Hg) and mean diastolic blood
pressure (3.6 mm Hg) were documented in the definite re-
current myocardial infarction cohort (Table 4). There were
no changes in blood pressure in the year preceding the
myocardial infarction (Fig. 5). These decreases persisted
for at least the first year of follow-up and were unaffected
by adjustment for weight reduction and development of
congestive heart failure. The blood pressure reductions were
sustained for 3 years in a smaller cohort of men followed
up for that time period after a definite recurrent myocardial
infarction. Blood pressure for the nonmyocardial infarction
cohort remained constant over the period of I year before
and I year after myocardial infarction (Fig. 5). In the cohort
with suspected myocardial infarction, systolic blood pres-
sure also decreased. The results were not altered when pa-
tients received antihypertensive or diuretic medication dur-
ing the 2 year period (I year before myocardial infarction
and I year after myocardial infarction) were excluded from
analysis; this analysis probably also eliminated patients with
congestive heart failure.
The 1 and 3 year mortality rates after recurrent myo-
cardial infarction were approximately 2.5 times higher in
the combined definite or suspected myocardial infarction
group compared with the nonmyocardial infarction group
(p < 0.01) (Table 5). Patients with a decrease in blood
pressure after recurrent myocardial infarction had consist-
ently higher mortality rates than did comparable patients
whose blood pressure increased or remained the same, but
these differences were not statistically significant.
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Figure 2. Five year event rates (per 100) related to systolic blood
pressure (SYS BP),withunadjusted (solid line)andadjusted (dashed
line) regression lines. t = t value for the coefficient "b" for the
univariate linear regression analysis (y= a+ bx), where x is sys-
tolic blood pressure and y is the specified end point. tl9 = t value
for the coefficient' 'b,' for the multivariate linearregression anal-
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blood pressure and the 19 other baseline variables listed in Ap-
pendix A are considered.
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hospitalization ; two-thirds of hypertensive patient s regained
their hypertension, half before discharge from the hospital
and the other half within I to 2 years . The level of blood
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Figure 3. Five year event rates (per 100) related to diastolic blood
pressure (DIA BP) withunadjusted(solid line) andadjusted (dashed
line) regression lines. Format as in Figure 2.
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Discussion
Prognostic significance of blood pressure after myo-
cardial infarction. Althou gh hypertension is a documented
major risk factor for first coronary events (1-9) and pre-
myocardial infarction hyperten sion appears to impair the
long-term outlook after recovery (17), little is known about
the prognostic relation between blood pressure elevation and
its associated characteristics in patient s after recovery from
myocardial infarction. Limited data are available about change
in blood pressure level and either disappe arance or devel-
opment of hypertension among survivors of myocardial in-
farction. Systolic and diastoli c blood pressure levels in post-
myocardial infarction patients are highly correlated (I' =
0.76): this has been previously reported (18) for general
populations. Nevertheless , 12% of the patients have isolated
systolic hypertension, a condition that appears progressively
prevalent after age 60. It is common in individuals with
extensive large systemic artery arteriosclerosis and , thus, is
expected to be frequent in survivors of myocardial infarction.
The 5 year pro gnosis fo r men with combined systolic and
diastolic hypertension at base line in the placebo group was
characterized by an increase in mortality from all causes,
major coronary events and combined cerebrovascular events
as compared with values in normotensive men . Values were
23. 1 versus 19.7%, 30.6 versus 25.0% and 13.3 versus
8.8~ , respectively. The increase in combined cerebrovas-
cular events remains statistically significant after adjustment
for 19 baseline variables. The physician' s interpretation of
symptoms meeting the criteria for transient stroke or tran-
sient ischemic attack may have varied significantly, making
these items and the combin ed cerebrovascular events end
point a less precisely defined end point than the cardiac end
point s. Even after control for the 19 baseline variables, the
association between an elevated systolic blood pressure and
major coronary events and cerebrovascular events remained
statistically significant (Fig . 2). Isolated systolic hyperten-
sion also significantly increased the risk of mortalit y from
all causes. Because systolic blood pressure is a major con-
tributor to myocardial oxygen demand , systolic blood pres-
sure elevation is likely to exacerbate the clinical manifes-
tations of myocardial ischemia and adversely affect prognosis.
In a prospective epidemiologic study (8,9), isolated systolic
hypertension was associated with a two- to threefold in-
crease in mortality from all causes, as well as cardiovascular
and coronary mortality in both men and women.
Previous studies. Many prior studies assessing the prog-
nostic significance of blood pressure elevation after myo-
cardial infarction were based on in-hospital determinations
during the acute illness; these data cannot be compared with
those of the present study . The blood pressure decrease
described by Master et al. (19) in 538 patients with initial
and recurrent myocardial infarction was maximal during the
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Figure 4. Five year event rates (per 1(0), unadjusted observed
(OBS) (bars) and adjusted for 19 baseline variables, for subsets
defined by baseline systolic and diastolic 8190d pressures. Nor-
motension : systolic blood pressure less than 140 mm Hg, diastolic
blood pressure less than 90 mm Hg (1,92 1 men); isolated diastolic
hypertension: systolic blood pressure less than 140 mm Hg; dia-
stolic blood pressure of 90 mm Hg or greater (132 men); isolated
systolic hypertension : systolic blood pressure of 140 mm Hg or
greater, diastolic blood pressure less than 90 mm Hg (337 men);
combined hypertension: systolic blood pressure of 140 mm Hg or
greater, diastolic blood pressure of 90 mm Hg or greater (339
men). t value for compariso n with normotension group, * denotes
a p value < 0.01 for comparison with normotension group.
pressure after myocardial infarction did not influence prog-
nosis. Astrup et al. (20) reported on normotension persisting
up to 8 weeks after myocardial infarction in 37 of 58 pre-
viously hypertensive patients, but presented no long-term
data. Gibson (21) described a considerable decrease in blood
pressure early after myocardial infarction, without taking
into consideration the possible effects of heart failure, di-
uretic therapy, sedatives and narcotics .
In the Multiple Risk Factor Intervention Trial with re-
cruitment involving approximately 361,000 persons aged
between 35 and 57 years , nearly 6,000 were immediately
eliminated because they had been hospitalized for a myo-
cardial infarction; nevertheless , they had their blood pres-
sure and serum cholesterol levels measured and a smoking
history obtained , During 5 years of follow-up, patients with
myocardial infarction had a mortality rate five times that of
patients without this finding; hypertension was indepen-
dently related to the risk of death in this subset of patients
as well as in other subsets (22).
Table 4. Blood Pressure Before and After Recurrent Myocardial Infarction
Definite MI Suspected MI No MI*
Systolic BP
Mean pre-MIt 134.7 133.1 131.7
Mean post-Ml 126.8 126.9 132.0
Mean difference -7.9 -6.2 0.3
Paired t value -7.57 -3.32 0.95
Diastolic BP
Mean pre-MI 84.0 81.6 81.8
Mean post-MI 80.4 80.2 82.2
Mean difference -3 .6 - 1.5 0.4
Paired t value -6.13 -1.20 1.66
No. of men 326 68 1,822
*Mean values for pre- and postmyocardial infarction based on randomly selected follow-up visit. t Average
4 month time interval between pre- and postmyocardial infarction blood pressure measurement. BP = blood
pressure; MI == myocardial infarction .
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Figure 5. Blood pressure (BP) levels for three premyocardial in-
farction (MI) visits and three postmyocardial infarction visits for
definite myocardial infarction cohort (186 men), suspected myo-
cardial infarction cohort (58 men) and no myocardial infarction
cohort (l,222 men).
hypertensive treatment with thiazide diuretics. More than
one-fourth (28%) of the patients taking no medication in-
fluencing blood pressure at baseline began diuretic or an-
tihypertensive medication during 5 years of follow-up. Re-
cent general population studies (3,23,24) among white and
black men and women have shown similar positive corre-
lations between relative body weight, heart rate, plasma
glucose, serum uric acid and blood pressure independent of
the confounding effects of diuretic and other antihyperten-
sive medications.
Decrease in blood pressure after recurrent myo-
cardial infarction and its prognostic significance.
Statistically significant decreases in both systolic and dia-
stolic blood pressures occurred after recurrent myocardial
infarction and persisted during at least 1 year of follow-up
(through 3 years of follow-up in the smaller cohort of men
followed up for this time period). The group of patients
with suspected' recurrent myocardial infarction also had a
decrease in systolic blood pressure. Although not statisti-
cally significant, a decrease in blood pressure suggests a
less favorable prognosis, a finding consistent with Fra-
mingham data (25). In that study, disappearance of prior
hypertension after myocardial infarction was associated with
a twofold increased risk of death, presumably because it
reflected severe pump dysfunction. In the Coronary Drug
Project, few patients had significant congestive heart failure
after recurrent myocardial infarction as evidenced by use of
diuretic drugs. In our study, some patients with a major
decrease in blood pressure may have died before the post-
myocardial infarction visit and, thus, would not be included
in the analysis.
Mechanism of blood pressure decrease after reinfarc-
tion. The decrease in blood pressure after myocardial in-
farction did not result from weight loss i~ the patients in
the Coronary Drug Project. It is also apparently not a con-
sequence of overt heart failure. Given the poorer prognosis,
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It I~ not surprising that blood pressure elevation in sur-
vivors of myocardial infarction has prognostic significance;
however, the predictive power in relative terms is less than
that of hypertension in patients without myocardial infarction.
Correlates of blood pressure after myocardial infarc-
tion. As is the case before myocardial infarction, increasing
age correlates with baseline systolic hypertension. Increased
relative body weight and ST depression on the electrocar-
diogram were other important correlates. Elevated serum
uric acid and elevated plasma glucose levels are correlates
of baseline hypertension, in part as a side effect of anti-
Table 5. I and 3 Year Mortality Rates After Recurrent Myocardial Infarction by Changes in
Blood Pressure Pre- to Postmyocardial Infarction
Definite or Suspected MI No MI*
No. of Men Rate (%) No. of Men Rate (%)
I Year mortality 385 9.4 1,743 3.8
SBP decrease 228 I 1.4 722 4.3
Same or increase 157 6.4 1,021 3.5
DBP decrease 201 11.0 655 4.4
Same or increase 184 7.6 1,088 3.5
3 Year mortality 291 33.7 1,304 13.8
SBP decrease 173 37.0 551 15.2
Same or increase 118 28.8 753 12.7
DBP decrease 147 36.0 478 14.4
Same or increase 144 31.2 826 13.4
*Values for pre- and postmyocardial infarction based on randomly selected follow-up visit. DIW = diastolic
blood pressure; MI = myocardial infarction; SBP = systolic blood pressure.
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or at least the trend of our data to agree with the Framingham
results (25), decreased blood pressure may relate in part to
damage to the heart as a pump. Possible mechanisms for
the decrease in blood pressure after myocardial infarction
range from loss of reflex mechanisms that elevate blood
pressure to accentuationof controlor modulatingmechanisms.
McCall et al. (26) described a sustained decrease in sys-
tolic and diastolic blood pressures in 21 men after an initial
myocardial infarction, maintained for 2 years and unrelated
to weight loss. Their postmyocardial infarction blood pres-
sure levels were greater than Coronary Drug Project pre-
myocardial infarction blood pressure levels, allowing for a
greater decrease. The correlation of serum glutamic oxal-
oacetic acid elevation during the acute event with decreased
blood pressure suggests that this decrease is at least in part
a consequence of loss of myocardial tissue.
Appendix A
Entry Characteristics Evaluated for Relation
to Long-Term Prognosis of Middle-Aged Men
Recovered From Myocardial Infarction
Demographic characteristics
*1. Age
*2. Race
Clinical characteristics
*3. Risk
*4. Number of myocardial infarctions
*5. Time from last myocardial infarction to entry into Coro-
nary Drug Project
6. New York Heart Association functional class
7. History of congestive heart failure
8. History of acute coronary insufficiency
9. History of angina pectoris
10. History of intermittent claudication
II. History of intermittent cerebral ischemic attack
12. Use of digitalis
13. Use of diuretic drugs
14. Use of antiarrhythmic drug
15. Use of antihypertensive agents
16. Use of oral medication for hypoglycemia
17. Cardiomegaly on chest X-ray film
Electrocardiographic characteristics
18. Q or QS findings, or both
19. ST segment depression
20. T wave findings
21. ST segment elevation
22. Frequent ventricular ectopic beats
23. Ventricular conduction defects
24. Heart rate
Coronary risk factors
*25. Serum cholesterol
*26. Fasting serum triglycerides
27. Diastolic blood pressure
28. Systolic blood pressure
*29. Cigarette smoking
*30. Fasting plasma glucose
*31. Plasma glucose I hour after 75g oral load
*32. Serum uric acid
*33. Physical inactivity during leisure time
*34. Relative body weight
Other biochemical characteristics
*35. Serum alkaline phosphatase
*36. Serum total bilirubin
*37. Plasma urea nitrogen
Hematologic characteristics
*38. Hematocrit
*39. White blood count
*40. Absolute neutrophil count
*19 adjusting variables
Appendix B
Diagnostic Criteria for
Cardiovascular Events
The following criteria are used to diagnose cardiovascular events
that occur during the follow-up period of the study.
I, Recurrent Myocardial infarction
A diagnosis ofdefinite recurrent myocardial infarction is made
if any of the following are satisfied:
A. There is development of new abnormal Q wave findings
not present on the patient's last electrocardiogram.
B. There are clinical symptoms compatible with myocardial
infarction in conjunction with serum enzyme elevation and
newly developed nonspecific electrocardiographic findings
(such as ST segment changes, T wave changes, ventricular
conduction defects, atrioventricular conduction defects or
arrhythmias) .
C. There are clinical symptoms compatible with myocardial
infarction in conjunction with serum enzyme elevation with-
out electrocardiographic findings.
A diagnosis of suspected myocardial infarction is made when
there is a clinical picture compatible with myocardial infarction
and either of the following conditions:
A. There is development of new nonspecific electrocardio-
graphic findings (such as ST-T changes, etc.), but only
borderline serum enzyme elevations or enzyme studies are
not done.
B. There are no new electrocardiographic findings (or an elec-
trocardiogram not obtained) and only borderline serum en-
zyme elevations or enzyme studies are not done.
The differentiation between suspected myocardial infarction
and definite acute coronary insufficiency may be difficult and often
arbitrary, especially in the case of ST-T changes without elevated
serum enzyme levels. The investigator must exercise the best clin-
ical judgment in arriving at a decision.
2. Acute Coronary insufficiency
For the purposes of the Coronary Drug Project, acute coronary
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insufficiency signifies prolonged discomfort of cardiac origin with-
out conclusive evidence of myocardial infarction.
Definite acute coronary insufficiency is reported when a patient
experiences chest pain considered to be of cardiac origin lasting
longer than 30 minutes and associated with no diagnostic change
in Q waves but significant ST-T changes from pre-event records
and with the absence of diagnostic serum enzyme levels. (It is
recognized that intramural myocardial infarction as well as trans-
mural myocardial infarction in some cases may be included in this
category.)
Suspected acute coronary insufficiency is reported when a pa-
tient experiences chest pain considered to be of cardiac origin
lasting longer than 30 minutes, but not associated with any sig-
nificant ST-T wave changes (or an electrocardiogram is not ob-
tained In connection with the event).
3. Angma Pectoris
A diagnosis of definite angina pectoris is made when there are
episodes of' 'cardiac" pain, aching, tightness or pressure that may
or may not radiate to the left neck, jaw, shoulder or arm, and: a)
the discomfort is usually related to effort; b) the discomfort is
relieved by rest in less than 10 minutes; and/or c) if nitroglycerin
is used, the discomfort is relieved in less than 10 minutes.
Suspected angina pectoris is reported if the patient has pain
that seems to be cardiac in origin and a, band c are equivocal
or absent.
4. Congestive Heart Failure
The diagnosis is made in the presence of symptoms and clinical
or radiologic signs of pulmonary congestion or edema, and/or an
elevated systematic venous pressure (as determined clinically or
manometrically), and/or congestive hepatomegaly, ascites or pe-
ripheral edema. An associated ventricular gallop, often present, is
not a required criterion.
5. Stroke
Definite stroke is reported if all three of the following criteria
are met:
A. One or more of the following symptoms and/or one or more
of the following signs are present:
I. Carotid arterial system: weakness or numbness in the
contralateral limbs, contralateral homonymous hemi-
anopsia, dysphasia or agnosia.
2. Vertebral-basilar arterial system: weakness or numb-
ness of single or multiple limbs, numbness of the face
(particularly about the mouth), diplopia, dysphagia, dy-
sarthria, homonymous hemianopsia, ataxia, nystagmus
or altered consciousness.
B. The above symptoms or signs persist for longer than 24
hours.
e. Objective neurologic deficits or residua are present.
Events known to be precipitated by trauma or angiography or
related to central nervous system neoplasms, abscesses and so forth
are excluded.
Suspected stroke is diagnosed when one or more of the symp-
toms just outlined and/or one or more of the signs are present but
are equivocal, persist for more than 24 hours, and equivocal neu-
rologic deficits or residua are present.
6. lniermittent Cerebral Ischemic Attacks
Definite intermittent cerebral ischemic attack is diagnosed if
all three of the following criteria are met:
A. One or more of the following symptoms and/or one or more
of the following signs are present with the sign or signs
confirmed by physician observations:
I. Carotid arterial system: weakness or numbness in the
contralateral limbs, contralateral homonymous hemi-
anopsia, dysphasia or agnosia.
2. Vertebral-basilar arterial system: weakness or numb-
ness of single or multiple limbs, episodes of vertigo and
nausea, numbness of the face (particularly about the
mouth), diplopia, dysphagia, dysarthria, homonymous
hemianopsia, ataxia, nystagmus or altered consciousness.
B. The above symptoms or signs persist for less than 24 hours.
e. Objective neurologic deficits or residua are not present.
Suspected intermittent cerebral ischemia attack should be di-
agnosed if one or more symptoms are merely reported by the patient
and there are no neurologic signs confirmed by physician observation.
7. Intermittent Claudication
The diagnosis of intermittent claudication is based solely on
the evaluation of a carefully obtained medical history. Leg pain
is diagnosed as intermittent claudication when it possesses the
following characteristics:
A. Its site must include one or both calves and/or thighs and
hips.
B. It must be provoked by walking.
C. It must never start at rest.
D. It must make the patient either stop or slacken pace.
E. It must disappear on a majority of occasions within 10
minutes or less from the time when the patient stands still,
and should recur after a similar interval of walking if the
same pace is resumed.
8. Peripheral Arterial Occlusive Disease
This definite diagnosis is made if either of the following criteria
is satisfied: a) absent popliteal or femoral pulsations, or b) di-
minished arterial pulses exclusive of dorsalis pedis with one or
more of the following: elevation pallor, dependent rubor, pro-
longed return of color and venous filling after elevation or presence
of ischemic ulcers.
A suspected diagnosis is made when diminished arterial pulses
are present with the associated findings described in 6.
9. Pulmonary Embolism
A diagnosis of definite pulmonary embolism is made if the
following criteria are satisfied:
A. One or more of the following symptoms: dyspnea, sub-
sternal or pleuritic chest pain, hemoptysis; and
B. Physical signs of one or more of the following: phlebitis,
tachypnea, acute right-sided failure, shock, pulmonary con-
solidation, pleural friction rub; and/or
C. Two or more of the following laboratory findings: I) roent-
genographic evidence of pulmonary infiltration, an elevated
diaphragm or pleural effusion; 2) elevated serum bilirubin
or lactic dehydrogenase; 3) electrocardiographic changes
consistent with acute right heart strain or dilation; 4) evi-
dence by pulmonary function studies of an increased ven-
tilatory dead space, that is, a reduction in the mean alveolar
carbon dioxide tension in the presence of a normal or nearly
normal arterial carbon dioxide tension.
Alternatively, item C is satisfied if one or both of the following
is available: I) results of pulmonary isotope scanning compatible
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with pulmonary embolism, or 2) results of selective pulmonary
angiography compatible with pulmonary embolism.
Suspected pulmonary embolism is diagnosed when the available
findings are equivocal or insufficient studies are carried out.
10. Thrombophlebitis
A diagnosis of definite thrombophlebitis is made if both of the
following criteria are met:
A. One or more of the following symptoms are present: lo-
calized pain in the affected extremity, swelling or change
of skin color of the extremity.
B. One or more of the following physical findings are present:
edema or mottled cyanosis of the extremity, a sudden in-
crease in the circumference of the limb, differential increase
in warmth of the extremity, pain in the calf and/or popliteal
space or dorsiflexion of the foot (Homan's sign) or a positive
sphygmomanometer cuff pain test (Lowenberg pain elicited
by a cuff inflated over the affected part to a level of 60 to
150 mm Hg).
A definite diagnosis may also be made in the presence of definite
or suspected pulmonary embolism and one or more of the preceding
symptoms or signs.
Suspected thrombophlebitis is diagnosed in the presence of one
symptom and equivocal physical findings.
11. Atrial Fibrillation
This includes atrial flutter or fibrillation, paroxysmal or sus-
tained, documented on an electrocardiogram.
12. Other Arrhythmias
The following cardiac arrhythmias. documented on an elec-
trocardiogram, are reported: a) supraventricular tachycardia, b)
ventricular tachycardia, c) nodal rhythm, d) ventricular rhythm,
e) ventricular fibrillation, f) multifocal ventricular premature beats,
g) runs of three or more ventriclar premature beats, and h) other
major arrhythmias. Sinus arrhythmias, supraventricular premature
beats and ventricular premature beats other than those just specified
are not reported.
13. Peripheral Arterial Embolism
Definite arterial embolism is documented by a history of sudden
coldness, paresthesias or pain of an extremity and clinical findings
of pallor, muscular weakness and loss of pulse. Angiographic or
surgical findings, when available, are used to corroborate the
diagnosis.
Suspected arterial embolism is designated when there is only
a history of coldness or pain of an extremity without physician
confirmation.
14. Arterial Aneurysm
Definite radiographic evidence of an aneurysm is required.
15. Cardiomegaly
Cardiomegaly constitutes a definite increase in heart size on
comparison of two or more posteroanterior chest roentgenograms.
The criterion employed by the local radiologists for determining
this diagnosis is acceptable for the study. Other conditions resulting
in cardiomegaly (for example, pericarditis and myocarditis) should
be considered and excluded, if possible, before cardiomegaly is
attributed to coronary artery disease.
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